Home > Oncology > ESMO 2020 > Lung Cancer > No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC

No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ESMO 2020
The merits of post-operative radiotherapy (PORT) in completely resected non-small cell lung cancer (NSCLC) patients have been under debate for many years. The prospective phase 3 LungART trial now demonstrated that PORT cannot be recommended as a standard of care in all completely resected stage IIIA N2 NSCLC patients [1]. To evaluate the value of PORT in completely resected stage IIIA N2 NSCLC patients, the phase 3 LungART trial was developed. Patients were eligible if they were performance status 0-2, had a complete resection with nodal exploration, and proven N2 disease; prior (neo)-adjuvant chemotherapy was allowed. LungART enrolled 501 patients: 252 patients were randomised to PORT (54 Gy/27-30 fractions), and 249 to the control arm (no PORT). In the PORT arm, 96% of the patients received the dose of 54 Gy. Median disease-free survival (DFS) in the PORT arm was 30.5 months versus 22.8 months in controls (HR 0.85; P=0.16). DFS at 3 years follow-...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on